Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ramya Pakala"'
Autor:
Prathima Guntipalli, Sirisha Gara, Sujan Poudel, Aakash Hans, Muhammad Abdullah Usman, Deeksha Dhar, Ramya Pakala, Sangam Shah, Sangharsha Thapa, Sudarshan Acharya, Kester J. Nedd, Sam Kara
Publikováno v:
Acta Neurobiologiae Experimentalis.
Neurodegenerative disorders (NDD) are chronic neurological diseases characterized by loss and/or damage to neurons along with the myelin sheath, and patients are at higher risk of severe infection with the SARS‑CoV‑2. A comprehensive literature s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f81cfb75939e9a2c4fdf3f82b450f77b
https://doi.org/10.55782/ane-2022-040
https://doi.org/10.55782/ane-2022-040
Autor:
M.-K. Endaya Coronel, A Bhatnagar, Endrit Shahini, G Enebong Nya, A.G. Solimando, S Ahmed, Aminah Abdul Razzack, R Ranaldo, Ramya Pakala, R Cozzolongo, S Kumari Gara, Faiza Ahmed, Prathima Guntipalli, Kim Andrews, Andre Thompson
Publikováno v:
Acta Gastro Enterologica Belgica. 84:633-652
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma, resulting in major global public health concerns. The HCV infection is unevenly distributed worldwide, with variations in prevalen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ebf850c184955375a7e67db722ccb77
https://doi.org/10.51821/84.4.015
https://doi.org/10.51821/84.4.015
Autor:
Sekhar K Ch, Ramya Pakalapati, Balaji Mugada, Anusha Kalluri, Raviteja Surakasi, Iván Leandro Rodríguez Rico
Publikováno v:
ITEGAM-JETIA, Vol 10, Iss 48 (2024)
The experiment yielded significant findings. Transesterification was used to turn waste cooking oil into biodiesel, a renewable energy source. The fuel mixture ratios were adjusted to measure engine performance and lower fossil fuel emissions. The st
Externí odkaz:
https://doaj.org/article/2d3fb13edbde4cf8b03172aedad4d2fd
Autor:
Mohamad Mouchli, Faiza Ahmed, Prathima Guntipalli, Faris Pacha, Farhan Khalid, Karthik Mohan, Godsgift Enebong Nya, Sirisha Gara, Sakshi Mishra, Ramya Pakala, Nazma Hanif, Mobeen Zaka Haider, Andre Thompson, R. Garimella, Israr Khan, Kim Andrews
Publikováno v:
Journal of Clinical Oncology. 39:e21150-e21150
e21150 Background: Capmatinib is a selective inhibitor of MET receptor that got accelerated FDA approval in May 2020 to treat NSCLC with MET ex 14 mutation (METex14). Here, we proclaim the first review of capmatinib efficacy and safety profile in MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c8838c57c08a9a4f57240c32b5ee26d
https://doi.org/10.1200/jco.2021.39.15_suppl.e21150
https://doi.org/10.1200/jco.2021.39.15_suppl.e21150